NR1H4 and cholestasis: Despite promising results emerging from experimental models or clinical trials, significant side effects appeared during the therapy such as altered cholesterol levels, exacerbation of liver injury or cholestasis implying the potential use of FXR antagonists in the treatment of these disorders (Stedman et al., 2006; Lamers et al., 2014).